Search research articles
Contact Us
Filters
Showing results (181-190 of 1,324) with videos related to
Page
of 133
Sort By:
Expert Opinion on Investigational Drugs
|
December 27, 2018
Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date
Renee-Marie Ragguett, Carola Rong, Kevin Kratiuk, et al.
Current Pharmaceutical Design
|
January 13, 2017
Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD
Zihang Pan, Joshua D Rosenblat, Walter Swardfager, et al.
Journal of Affective Disorders
|
November 17, 2022
The Motivation and Energy Inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study
Michael Cronquist Christensen, Michael Adair, Henrik Loft, et al.
Current Medical Research and Opinion
|
December 29, 2015
Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder
Roger S McIntyre, Rana Fayyad, Joan A Mackell, et al.
Dialogues in Clinical Neuroscience
|
June 2, 2017
Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders
Mehala Subramaniapillai, Nicole E Carmona, Carola Rong, et al.
Canadian Family Physician Medecin De Famille Canadien
|
August 21, 2004
Treating bipolar disorder. Evidence-based guidelines for family medicine
Roger S McIntyre, Deborah A Mancini, Peter Lin, et al.
Psychosomatics
|
March 18, 2014
Metabolic syndrome and elevated C-reactive protein levels in elderly patients with newly diagnosed depression
Soyeon Park, Yeon Ho Joo, Roger S McIntyre, et al.
European Child & Adolescent Psychiatry
|
April 8, 2014
Risk factors for incident major depressive disorder in children and adolescents with attention-deficit/hyperactivity disorder
Jeanette M Jerrell, Roger S McIntyre, Yong-Moon Mark Park
CNS Drugs
|
November 12, 2025
The Potential Clinical Use of Opioid-Receptor-Modulating Drugs in Bipolar Disorder
Maria Gefke, Christina B Wagner, Roger S McIntyre, et al.
Journal of Affective Disorders
|
July 20, 2024
Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder
Roger S McIntyre, Oscar Necking, Simon Nitschky Schmidt, et al.
Page
of 133
Search research articles
Search
Showing results (181-190 of 1,324) with videos related to
Sort By:
Page
of 133
Expert Opinion on Investigational Drugs
|
December 27, 2018
Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date
Renee-Marie Ragguett, Carola Rong, Kevin Kratiuk, et al.
Current Pharmaceutical Design
|
January 13, 2017
Role of Proinflammatory Cytokines in Dopaminergic System Disturbances, Implications for Anhedonic Features of MDD
Zihang Pan, Joshua D Rosenblat, Walter Swardfager, et al.
Journal of Affective Disorders
|
November 17, 2022
The Motivation and Energy Inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study
Michael Cronquist Christensen, Michael Adair, Henrik Loft, et al.
Current Medical Research and Opinion
|
December 29, 2015
Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder
Roger S McIntyre, Rana Fayyad, Joan A Mackell, et al.
Dialogues in Clinical Neuroscience
|
June 2, 2017
Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders
Mehala Subramaniapillai, Nicole E Carmona, Carola Rong, et al.
Canadian Family Physician Medecin De Famille Canadien
|
August 21, 2004
Treating bipolar disorder. Evidence-based guidelines for family medicine
Roger S McIntyre, Deborah A Mancini, Peter Lin, et al.
Psychosomatics
|
March 18, 2014
Metabolic syndrome and elevated C-reactive protein levels in elderly patients with newly diagnosed depression
Soyeon Park, Yeon Ho Joo, Roger S McIntyre, et al.
European Child & Adolescent Psychiatry
|
April 8, 2014
Risk factors for incident major depressive disorder in children and adolescents with attention-deficit/hyperactivity disorder
Jeanette M Jerrell, Roger S McIntyre, Yong-Moon Mark Park
CNS Drugs
|
November 12, 2025
The Potential Clinical Use of Opioid-Receptor-Modulating Drugs in Bipolar Disorder
Maria Gefke, Christina B Wagner, Roger S McIntyre, et al.
Journal of Affective Disorders
|
July 20, 2024
Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder
Roger S McIntyre, Oscar Necking, Simon Nitschky Schmidt, et al.
Page
of 133